Corrigendum to ‘Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer’ [Journal of Thoracic Oncology, Volume 19 Issue 1 (2024) 119-129]

Lara-Mejía L.; Cardona A.F.; Mas L.; Martin C.; Samtani S.; Corrales L.; Cruz-Rico G.; Remon J.; Galvez-Nino M.; Ruiz R.; Rios-Garcia E.; Tejada F.; Lozano-Vazquez N.; Rosell R.; Arrieta O. · Journal of Thoracic Oncology (2026) · DOI: 10.1016/j.jtho.2025.10.004

Resumen

The authors regret that Table 2 has an unintended mistake in the “Overall Population” column, where the sample size should have been 109 instead of 116. This sample corresponds to the evaluable population. This subheading was also corrected. It is important to mention that this correction does not alter the statistical significance of our analysis. In Table 3, we identified a reporting error regarding the complete response rate for patients without CDKN2A/B loss. The correct number is 5 patients (23.8%). Also, table subheading was corrected to make it clearer. In addition, we noticed that the first paragraph of the subsection Genomic Coalterations has a discrepancy. The presented percentage (62.4%) the corrected proportion should be 67.4%. As with prior adjustments, this change does not impact on the conclusions of our study. Lastly, we acknowledge a labelling error in Supplementary Figure 2. In the life tables, two subgroup names are incorrectly assigned: CDKN2A/B(-)/TP53wt and CDKN2A/B(+)/TP53mt. The authors would like to apologise for any inconvenience caused. Although these corrections do not alter the study’s conclusions, they contribute to the overall accuracy and quality of our article.

Instituciones: Universidad Privada San Juan Bautista